BRPI0413860A - [1,8] Naphthyridin-2-ones and related compounds for the treatment of schizophrenia. - Google Patents

[1,8] Naphthyridin-2-ones and related compounds for the treatment of schizophrenia.

Info

Publication number
BRPI0413860A
BRPI0413860A BRPI0413860-0A BRPI0413860A BRPI0413860A BR PI0413860 A BRPI0413860 A BR PI0413860A BR PI0413860 A BRPI0413860 A BR PI0413860A BR PI0413860 A BRPI0413860 A BR PI0413860A
Authority
BR
Brazil
Prior art keywords
treatment
schizophrenia
related compounds
naphthyridin
ones
Prior art date
Application number
BRPI0413860-0A
Other languages
Portuguese (pt)
Inventor
Jerry Clark
Jamie Davis
David Favor
Lorraine Fay
Lloyd Franklyn
Kevin Henegar
Douglas Johnson
Brian Nichelson
Ligong Ou
Joseph Thomas Repine
Michael Walters
Andrew David White
Zhijian Zhu
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34216117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0413860(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0413860A publication Critical patent/BRPI0413860A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"¢1,8!NAFTIRIDIN-2-ONAS E COMPOSTOS RELACIONADOS PARA O TRATAMENTO DA ESQUIZOFRENIA". Esta inveção se refere a compostos da fórmula 1 em que G, A, Z, Q, X, Y e R¬ 1¬ e R¬ 2¬ são definidos como na descrição, a composições farmacêuticas que os contêm e à sua utilização no tratamento de distúrbios do sistema nervoso central e de outros distúrbios."¢ 1.8! NAFTIRIDIN-2-ONAS AND RELATED COMPOUNDS FOR TREATMENT OF SCHIZOPHRENIA". This invention relates to compounds of formula 1 wherein G, A, Z, Q, X, Y and R¬1¬ and R¬2¬ are defined as in the description, the pharmaceutical compositions containing them and their use in the treatment. central nervous system disorders and other disorders.

BRPI0413860-0A 2003-08-22 2004-08-13 [1,8] Naphthyridin-2-ones and related compounds for the treatment of schizophrenia. BRPI0413860A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49737003P 2003-08-22 2003-08-22
PCT/IB2004/002665 WO2005019215A1 (en) 2003-08-22 2004-08-13 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Publications (1)

Publication Number Publication Date
BRPI0413860A true BRPI0413860A (en) 2006-10-24

Family

ID=34216117

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413860-0A BRPI0413860A (en) 2003-08-22 2004-08-13 [1,8] Naphthyridin-2-ones and related compounds for the treatment of schizophrenia.

Country Status (35)

Country Link
US (3) US7160888B2 (en)
EP (1) EP1660497A1 (en)
JP (1) JP4034811B2 (en)
KR (2) KR100765668B1 (en)
CN (1) CN100422181C (en)
AP (1) AP2006003525A0 (en)
AR (1) AR045386A1 (en)
AU (1) AU2004266191B2 (en)
BR (1) BRPI0413860A (en)
CA (1) CA2538915C (en)
CR (2) CR8254A (en)
CU (1) CU23464B7 (en)
EA (1) EA009645B1 (en)
EC (1) ECSP066391A (en)
GE (1) GEP20084447B (en)
GT (1) GT200500007A (en)
HN (1) HN2004000319A (en)
IL (1) IL173439A0 (en)
IS (1) IS8267A (en)
MA (1) MA28003A1 (en)
ME (1) MEP45308A (en)
MX (1) MXPA06002070A (en)
MY (1) MY140693A (en)
NL (1) NL1026892C2 (en)
NO (1) NO20060324L (en)
NZ (1) NZ545078A (en)
OA (1) OA13238A (en)
PA (1) PA8609701A1 (en)
PE (1) PE20051039A1 (en)
RS (1) RS20060129A (en)
TN (1) TNSN06063A1 (en)
TW (1) TWI298327B (en)
UA (1) UA82541C2 (en)
WO (1) WO2005019215A1 (en)
ZA (1) ZA200601526B (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904723D0 (en) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (en) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
ES2323451T7 (en) 2001-07-20 2011-08-01 Psychogenics Inc. TREATMENT FOR HYPERACTIVITY DISORDER WITH DEFICIT OF ATTENTION.
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MXPA06013941A (en) 2004-06-08 2007-12-10 Neurosearch Sweden Ab New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission.
ES2346452T3 (en) * 2004-06-08 2010-10-15 Nsab, Filial Af Neurosearch Sweden Ab, Sverige NEW DISABLED PHENYLPIPERIDINS / PIPERAZINS USED AS MODULATORS OF THE DOPAMINE NEUROTRANSMISSION.
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
FR2877005A1 (en) * 2004-10-22 2006-04-28 Bioprojet Soc Civ Ile NEW ARYLPIPERAZINE DERIVATIVES
US7511035B2 (en) 2005-01-25 2009-03-31 Glaxo Group Limited Antibacterial agents
WO2006090272A1 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2006103559A1 (en) * 2005-04-01 2006-10-05 Warner-Lambert Company Llc Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
GEP20105053B (en) * 2005-04-08 2010-07-26 Pfizer Prod Inc Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
RU2402549C3 (en) * 2005-04-14 2022-03-10 Оцука Фармасьютикал Ко., Лтд. PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR THE TREATMENT OF MENTAL DISORDERS
JP4315393B2 (en) * 2005-04-14 2009-08-19 大塚製薬株式会社 Heterocyclic compounds
AR055203A1 (en) 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd BENZOTIOPHENE DERIVATIVES WITH ANTIPSYTICAL PROPERTIES
CN102746298A (en) 2005-10-07 2012-10-24 埃克塞里艾克西斯公司 Pyridopyrimidinone inhibitors of Pl3K[alpha]
SE529246C2 (en) 2005-10-13 2007-06-12 Neurosearch Sweden Ab New disubstituted phenyl-piperidines as modulators of dopamine neurotransmission
WO2007052104A2 (en) * 2005-10-31 2007-05-10 Pfizer Products Inc. Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-but oxy]-3,4-dihydro-1h-[1,8]naphthyridin-2-one
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
WO2007116265A1 (en) * 2006-03-31 2007-10-18 Pfizer Products Inc. Process for making a tetrahydro-pyridoazepin-8-one compound
WO2007136790A2 (en) 2006-05-18 2007-11-29 Mannkind Corporation Intracellular kinase inhibitors
PT2074122E (en) * 2006-09-15 2011-08-24 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
US20100093738A1 (en) * 2006-10-06 2010-04-15 Basf Se Fungicidal Compounds and Fungicidal Compositions
JP4540700B2 (en) * 2006-10-13 2010-09-08 大塚製薬株式会社 Medicine
AR063302A1 (en) * 2006-10-13 2009-01-21 Otsuka Pharma Co Ltd DERIVATIVES OF 4-BENZO [B] TIOFEN-4-IL-PIPERAZIN-1-IL WITH ANTAGONIST ACTION OF THE 5-HT2A SEROTONINE RECEIVER AND ADRENALINE ALFA1 RECEPTOR AND PARTIAL AGRONIST OF THE D2 RECEPTOR, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND UNDERSTANDS TO PRODUCE IT.
WO2008084324A1 (en) * 2007-01-04 2008-07-17 Pfizer Products Inc. Naphthyridinone compound
JP4785881B2 (en) * 2007-02-27 2011-10-05 大塚製薬株式会社 Medicine
CL2008001002A1 (en) 2007-04-11 2008-10-17 Actelion Pharmaceuticals Ltd COMPOUNDS DERIVED FROM OXAZOLIDINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO PREPARE A MEDICINAL PRODUCT TO TREAT A BACTERIAL INFECTION.
JP5466147B2 (en) * 2007-05-21 2014-04-09 レビバ ファーマシューティカルズ，インコーポレーテッド Composition, synthesis and method of use of quinolinone atypical antipsychotic drugs
CL2008001563A1 (en) * 2007-05-30 2008-10-10 Wyeth6 3 COMPOUNDS DERIVED FROM BENZODIOXANES CONDENSED WITH HETEROCICLES; PREPARATION METHOD; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS DEPRESSION, ANXIETY, PANIC CRISIS, AMONG OTHERS.
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
PL2245028T3 (en) 2007-12-18 2012-07-31 Actelion Pharmaceuticals Ltd 5-aminocyclylmethyl-oxazolidin-2-one derivatives
US8653069B2 (en) 2008-07-28 2014-02-18 Jiangsu Hengyi Pharmaceutical Co., Ltd. Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia
ES2915065T3 (en) 2008-07-31 2022-06-20 Firmenich Incorporated Procedures for making sweet flavor enhancers
AU2009325902B2 (en) 2008-12-12 2015-01-29 Idorsia Pharmaceuticals Ltd 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives
CN102341394B (en) * 2009-01-23 2015-04-15 武田药品工业株式会社 Poly (ADP-Ribose) Polymerase (PARP) Inhibitors
NZ595263A (en) * 2009-02-26 2013-06-28 Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
CA2937222C (en) * 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
ES2834973T3 (en) 2010-05-04 2021-06-21 Alkermes Pharma Ireland Ltd Process for the synthesis of oxidized lactam compounds
ES2691671T3 (en) 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
EA026115B1 (en) 2010-12-17 2017-03-31 Ф. Хоффманн-Ля Рош Аг Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
HUE065359T2 (en) 2011-03-18 2024-05-28 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising sorbitan esters
JO3227B1 (en) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd Piperazine-substituted benzothiophene deriveatives as antipsychotic agents
TWI579272B (en) 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 The hydrobromide salt of pridopidine
JP5952912B2 (en) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド Prodrugs of secondary amine compounds
JP6219918B2 (en) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド Pharmaceutical composition comprising glycerol ester
ES2765036T3 (en) 2012-03-19 2020-06-05 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
ES2950418T3 (en) 2012-03-19 2023-10-09 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
JP6345651B2 (en) * 2012-05-09 2018-06-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Heteroaryl compounds and methods of use thereof
EP2897592B1 (en) 2012-09-19 2020-02-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
BR112016021535A8 (en) 2014-03-20 2021-07-20 Alkermes Pharma Ireland Ltd kit comprising aripiprazole formulations having increased injection rates useful for the treatment of a central nervous system disorder and use
CN104785295B (en) * 2015-03-18 2018-03-06 杭州创培信息科技有限公司 A kind of preparation method of high selectivity dopamine platinum carbon catalyst
EP3317278B1 (en) 2015-07-01 2021-04-14 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
IL294124B2 (en) 2015-12-10 2024-02-01 Ptc Therapeutics Inc Methods for treating Huntington's disease
CN106242934A (en) * 2016-07-26 2016-12-21 云南民族大学 Oxidation synthesis method for beta-position C-H bond acetyl of ketone
US11407753B2 (en) * 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. Methods for treating huntington's disease
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTATIN MODULATORS AND USES OF THESE LATEST
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
EP3762379A1 (en) 2018-03-07 2021-01-13 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
MX2020009957A (en) 2018-03-27 2021-01-15 Ptc Therapeutics Inc Compounds for treating huntington's disease.
PL3814357T3 (en) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
EP3814345B8 (en) 2018-06-27 2024-10-30 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
BR112021002261A2 (en) 2018-08-07 2021-05-04 Firmenich Incorporated 5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
PE20211089A1 (en) * 2018-08-13 2021-06-14 Hoffmann La Roche NEW HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONACILGLICEROL LIPASE
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (en) 2019-03-05 2021-01-01 美商英塞特公司 Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020231977A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
CN114269755A (en) 2019-09-12 2022-04-01 豪夫迈·罗氏有限公司 4,4A,5,7,8, 8A-hexapyrido [4,3-B ] [1,4] oxazin-3-one compounds as MAGL inhibitors
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN114634479B (en) * 2020-12-16 2025-02-07 北京盈科瑞创新药物研究有限公司 A kind of piperazine derivative, preparation method and application thereof
US20240217977A1 (en) * 2021-03-31 2024-07-04 Blueprint Medicines Corporation Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds
WO2023186023A1 (en) * 2022-03-30 2023-10-05 苏州旺山旺水生物医药股份有限公司 N-substituted quinolinone compound, preparation method therefor and use thereof
CN114805081B (en) * 2022-05-20 2024-09-24 都创(上海)医药开发有限公司 A method for rapidly preparing 1-naphthylamine based on microchannel continuous flow technology

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5649361A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JPH07165720A (en) * 1988-10-31 1995-06-27 Otsuka Pharmaceut Co Ltd Carbostyril derivative and therapeutic agent for schizophrenia containing the same derivative
JP2608788B2 (en) * 1988-10-31 1997-05-14 大塚製薬 株式会社 Schizophrenia remedy
WO1990006303A1 (en) 1988-12-02 1990-06-14 Pfizer Inc. Arylpiperidine derivatives
DE69021645T2 (en) 1989-05-19 1996-02-22 Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J. N- (aryloxyalkyl) heteroarylpiperidines and heteroarylpiperazines, processes for their preparation and their use as medicaments.
US5350747A (en) * 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
FI920023A0 (en) * 1989-07-07 1992-01-03 Pfizer HETEROARYLPIPERAZINFOERENINGAR SOM ANTIPSYKOTISKA AEMNEN.
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
MX9201991A (en) * 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited DERIVATIVES OF PIPERAZINE AND PROCEDURE FOR ITS PREPARATION.
IE914218A1 (en) 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
KR19990067704A (en) 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 Pharmaceutical composition containing pyrrolopyrimidine as an adrenal cortical stimulating hormone free factor antagonist
CZ284157B6 (en) 1992-12-17 1998-08-12 Pfizer Inc. Pyrazole and pyrazolopyrimidine compounds per se and for treating diseases and pharmaceutical preparations based thereon
RU2130453C1 (en) 1992-12-17 1999-05-20 Пфайзер Инк. Substituted pyrazoles, pharmaceutical composition based on said, method of patient treatment, intermediate compound
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
FR2699918B1 (en) * 1992-12-30 1995-03-17 Pf Medicament Selective 5HY1D-5HT1B receptor ligands derived from indole-piperazine useful as medicaments.
JPH07247271A (en) * 1994-01-21 1995-09-26 Otsuka Pharmaceut Co Ltd 3,4-dihydrocarbostyril derivative
FR2731222A1 (en) 1995-03-02 1996-09-06 Pf Medicament NOVEL PIPERAZINE AMINOINDOLES CYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
JP2900130B2 (en) * 1995-03-16 1999-06-02 大塚製薬株式会社 Carbostyril derivative and therapeutic agent for schizophrenia containing the derivative
JP2987484B2 (en) * 1995-03-16 1999-12-06 大塚製薬 株式会社 Method for producing carbostyril derivative
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US6114334A (en) 1995-07-13 2000-09-05 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
AU4153496A (en) 1995-10-20 1997-05-07 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
JPH09241161A (en) 1996-03-08 1997-09-16 Nippon Shinyaku Co Ltd Medicine
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
FR2761071B1 (en) 1997-03-20 1999-12-03 Synthelabo DERIVATIVES OF QUINOLEIN-2 (1H) -ONE AND DIHYDROQUINOLEIN-2 (1H) - ONE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR2769912B1 (en) 1997-10-16 2000-03-10 Pf Medicament NEW 3-OXO- (2H) -1,2,4 TRIAZINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS
DE19747063A1 (en) * 1997-10-24 1999-04-29 Basf Ag New 3-substituted tetrahydropyridopyrimidinone derivatives
US6267784B1 (en) 1998-05-01 2001-07-31 Benz Research And Development Corporation Intraocular lens and haptics made of a copolymer
WO2001046177A1 (en) 1999-12-20 2001-06-28 Eli Lilly And Company Benzofuran derivatives
DE10041574A1 (en) 2000-08-24 2002-03-07 Merck Patent Gmbh Chromenonderivate
AU2002243394A1 (en) 2000-11-16 2002-06-24 Wyeth Aryloxy piperidinyl derivatives for the treatment of depression
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
AR032641A1 (en) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd RECEIVER SUBTIPE AGONIST 5-HT 1A.
MXPA03011769A (en) 2001-06-29 2004-04-02 Lundbeck & Co As H Novel heteroaryl derivatives, their preparation and use.
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Also Published As

Publication number Publication date
US20050043309A1 (en) 2005-02-24
MY140693A (en) 2010-01-15
PA8609701A1 (en) 2005-05-24
TNSN06063A1 (en) 2007-10-03
AU2004266191B2 (en) 2009-11-26
AR045386A1 (en) 2005-10-26
NL1026892C2 (en) 2005-11-21
CN100422181C (en) 2008-10-01
ECSP066391A (en) 2006-08-30
IL173439A0 (en) 2006-06-11
OA13238A (en) 2006-12-13
HK1091815A1 (en) 2007-01-26
NZ545078A (en) 2009-09-25
TW200524938A (en) 2005-08-01
EP1660497A1 (en) 2006-05-31
MXPA06002070A (en) 2006-05-19
NO20060324L (en) 2006-05-18
CA2538915A1 (en) 2005-03-03
HN2004000319A (en) 2010-06-09
KR100801794B1 (en) 2008-02-05
CR8254A (en) 2006-10-17
RS20060129A (en) 2008-06-05
KR20070053364A (en) 2007-05-23
AP2006003525A0 (en) 2006-02-28
KR20060071404A (en) 2006-06-26
WO2005019215A1 (en) 2005-03-03
AU2004266191A1 (en) 2005-03-03
JP4034811B2 (en) 2008-01-16
CU23464B7 (en) 2009-12-17
ZA200601526B (en) 2007-04-25
CA2538915C (en) 2010-06-15
US20060287309A1 (en) 2006-12-21
JP2007503386A (en) 2007-02-22
US20060287310A1 (en) 2006-12-21
CR9834A (en) 2008-04-21
EA009645B1 (en) 2008-02-28
IS8267A (en) 2006-01-26
MEP45308A (en) 2011-02-10
GEP20084447B (en) 2008-08-10
PE20051039A1 (en) 2005-12-12
US7160888B2 (en) 2007-01-09
UA82541C2 (en) 2008-04-25
NL1026892A1 (en) 2005-02-28
MA28003A1 (en) 2006-07-03
CN1839134A (en) 2006-09-27
TWI298327B (en) 2008-07-01
KR100765668B1 (en) 2007-10-10
GT200500007A (en) 2005-10-24
EA200600294A1 (en) 2006-08-25

Similar Documents

Publication Publication Date Title
BRPI0413860A (en) [1,8] Naphthyridin-2-ones and related compounds for the treatment of schizophrenia.
BR0314393A (en) Heterocyclic Substituted Piperazines for the Treatment of Schizophrenia
BRPI0415683A (en) norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
BRPI0415613A (en) novel diazaspiroalkane compounds and their use in the treatment of ccr8-mediated diseases
BR9909565A (en) Bicyclic derivatives of hydroxamic acid
BRPI0609719B8 (en) acetylenyl-pyrazole-pyrimidine derivatives as mgbur2 antagonists
BR0313676A (en) Pyrimidine derivatives and their use as cb2 modulators
BR0208338A (en) Pyridine Derivatives
BRPI0414948A (en) pyrazolo-e-imidazo pyrimidine derivatives
BR0209267A (en) Fused pyrimidines as corticotropin releasing factor (crf) antagonists
BR0111667A (en) New compounds
SE0104140D0 (en) Novel Compounds
BRPI0409977A (en) aminopropanol derivatives as sphingosine-1-phosphate receptor modulators
BR0308937A (en) Fused imidazo compounds
BRPI0407734A (en) adamantane derivatives, processes for their preparation and pharmaceutical compositions containing
BRPI0510453A (en) Substituted Morpholine Compounds for the Treatment of Central Nervous System Disorders
BRPI0410316A (en) compound, pharmaceutical composition, use of the compounds, and method of treating vr1-mediated disorders and for the treatment of pain disorders
BRPI0512974A (en) New Hydantoin Derivatives for the Treatment of Obstructive Airway Diseases
BRPI0418255A (en) unsubstituted piperazine and piperidine derivatives
BRPI0413245A (en) 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders
BR0314299A (en) Pyrrolidone derivatives as mao-b inhibitors
BRPI0415769A (en) dihydrobenzofuranyl alkanamines and pharmaceutical compositions containing them
BRPI0413094A (en) quinoline derivatives and their use in therapy
BR0212069A (en) Oral antidiabetic agents
BRPI0411891A (en) pyrazol [3,4-b] pyridin-6-ones as gsk-3 inhibitors

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 8A ANUIDADE.